RenovoCath developer RNXT cites Phase III survival benefit
RenovoCath developer RenovoCath is scaling commercial adoption of its FDA-cleared device and says interim Phase III data show a six-month survival benefit and fewer adverse events in pancreatic cancer.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.